DeNovo Solutions Revenue and Competitors

Denver, CO USA

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • DeNovo Solutions's estimated annual revenue is currently $8.4M per year.(i)
  • DeNovo Solutions's estimated revenue per employee is $130,500

Employee Data

  • DeNovo Solutions has 64 Employees.(i)
  • DeNovo Solutions grew their employee count by -3% last year.

DeNovo Solutions's People

NameTitleEmail/Phone
1
VPReveal Email/Phone
2
Director OperationsReveal Email/Phone
3
Director Innovation and TechnologyReveal Email/Phone
4
Security ManagerReveal Email/Phone
5
Storage Engineer/E2 SpecialistReveal Email/Phone
6
Principal Software DeveloperReveal Email/Phone
7
Senior Hardware EngineerReveal Email/Phone
8
Project ControllerReveal Email/Phone
9
Information System Security EngineerReveal Email/Phone
10
Test EngineerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.5M7-30%N/AN/A
#2
$2M205%N/AN/A
#3
$85.4M471-1%N/AN/A
#4
$1.5M17N/AN/AN/A
#5
$0.4M60%N/AN/A
#6
$1M1110%N/AN/A
#7
$0.3M4-20%N/AN/A
#8
$0.6M80%N/AN/A
#9
$2.3M23N/AN/AN/A
#10
$15.7M108-4%N/AN/A
Add Company

What Is DeNovo Solutions?

DeNovo Solutions, LLC is a Minority/Service Disabled Veteran Owned Small Business (SDVOSB) that delivers trusted professional and engineering services throughout the Intelligence Community (IC). Our Mission is to provide a new way of doing business with a focus on your business success. We make improving the competitive position of our customer paramount in importance and work collaboratively to ensure the best service possible. DeNovo Solutions provides cost competitive staffing solutions to our customers in Colorado, Maryland and Virginia.

keywords:N/A

N/A

Total Funding

64

Number of Employees

$8.4M

Revenue (est)

-3%

Employee Growth %

N/A

Valuation

N/A

Accelerator

DeNovo Solutions News

2022-04-17 - CareDx Showcases Leadership with Over 25 Oral Presentations and Posters at the International Society for Heart and Lung Transplantation Meeting

Data Highlights Clinical Utility of CareDx Solutions, ... for assessing the risk of rejection and de novo donor-specific antibodies (dnDSA).

2022-03-30 - OraSure Technologies’ Subsidiary DNA Genotek Launches the First Device with De Novo Authorization from the FDA for the Preservation and Stabilization of Microbiome Samples

... DNA Genotek Launches the First Device with De Novo Authorization from the ... President of Molecular Solutions for OraSure Technologies.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$14.6M643%N/A
#2
$18.5M6410%N/A
#3
$14.4M648%N/A
#4
$8.4M64N/AN/A
#5
$19.2M655%N/A